EXTON, Pa., June 1, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced the appointment of Michael F. Marino as Senior Vice President, General Counsel and Corporate Secretary, effective immediately. Mr. Marino is a seasoned legal advisor and executive with more than 14 years of experience advising publicly-traded and privately-held companies in a diverse range of industries—most notably life sciences, technology, manufacturing and banking, among others.
Prior to joining Fibrocell, Mr. Marino served as Senior Vice President, General Counsel and Secretary of NuPathe Inc., a NASDAQ-listed specialty pharmaceutical company that was acquired by Teva Pharmaceutical Industries Ltd. in 2014. Prior to NuPathe, Mr. Marino was an attorney at the law firms of Morgan, Lewis & Bockius LLP in Philadelphia and WilmerHale LLP in Boston, where his practice focused on mergers and acquisitions, joint ventures, financing transactions, corporate governance, securities law and general corporate law. Mr. Marino earned a B.S. in Accountancy from Villanova University and a J.D. from Boston College Law School.
"Michael's distinguished leadership and strategic counsel experience in life sciences will be invaluable as we continue to build Fibrocell's management team in leading the company to its next stage of growth in innovative cell and gene therapies," said David Pernock, Chairman and Chief Executive Officer.
"I am thrilled to be joining Fibrocell and work with a passionate team dedicated to developing groundbreaking treatment options for patients in need," said Mr. Marino. "Knowing our fibroblast-based therapeutics have the potential to be transformational—addressing the underlying cause of debilitating skin and connective tissue conditions—is both inspiring and exciting."
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. For more information, visit www.fibrocellscience.com.
This press release contains, and our officers and representatives may from time to time make, statements that are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, among others, statements we make regarding our development strategy, timing and potential advantages of our product candidates.
These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Fibrocell's control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) uncertainties relating to the initiation and completion of clinical trials; and (ii) whether clinical trial results will validate and support the safety and efficacy of our product candidates, as well as those set forth under the caption "Item 1A. Risk Factors" in Fibrocell's most recent Form 10-K filing.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. In addition, Fibrocell operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell's most recent annual report on Form 10-K, our most recent Form 10-Q as well as other public filings with the SEC since the filing of Fibrocell's most recent annual report.
CONTACT: Investor Relations Contact: Karen Casey Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, PA 19341 (484) 713-6133 firstname.lastname@example.orgSource:Fibrocell Science, Inc.